Ruboxistaurin

DB11829InvestigationalSmall molecule

Ruboxistaurin has been investigated for the basic science of Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus.

Mechanism: Pharmacologically active on Protein kinase C beta type, Protein kinase C alpha type, and Protein kinase C
Curator reviewed
Formula / weight: C₂₈H₂₈N₄O₃ · 468.5469 g/mol (avg)
Code names: DBI-102 · LY-333531

Resolves to

Compound

Structure

InChIKeyZCBUQCWBWNUWSU-SFHVURJKSA-NSMILESCN(C)C[C@@H]1CCN2C=C(C3=C2C=CC=C3)C2=C(C(=O)NC2=O)C2=CN(CCO1)C1=C2C=CC=C1

Targets

What you can answer from here — as of September 15, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ruboxistaurin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.